



Integrated Multidisciplinary Management of Diabetes Mellitus: Roles of Internal Medicine, Hematology, Nursing, Dental Care, Optometry, Health Informatics, Hospital Management, and Social Work

Hussain Mohammed Hussain Alwabari⁽¹⁾, Noura Ahmad Jaber Almalki⁽²⁾, Hanady Fahad Ayed Alhumaidani⁽³⁾, Ibrahim Ahmed Khabrani⁽⁴⁾, Ahed Fallah Jadaan Al Dhafiri⁽²⁾, Abrar Ali Khormi⁽⁵⁾, Mohammed Saad Alhelal⁽⁶⁾, Norah Mesfer Alqahtani⁽⁷⁾, Mohammed Hameed Alhelali⁽⁸⁾, Abdulaziz Jaad Saqr Al Osaimi⁽⁹⁾

(1) King Fahad Hospital Hofuf, Ministry of Health, Saudi Arabia,

(2) Ministry Of Health, Saudi Arabia,

(3) King Salman Bin Abdulaziz Hospital In Riyadh, Ministry of Health, Saudi Arabia,

(4) Eradah And Mental Health Hospital Jazan, Ministry of Health, Saudi Arabia,

(5) Jazan General Hospital, Ministry of Health, Saudi Arabia,

(6) Al Omran General Hospital, Ministry Of Health, Saudi Arabia,

(7) Riyadh Second Health Cluster, Chest Clinic In Rawdah, Ministry of Health, Saudi Arabia,

(8) Medina General Hospital, Ministry of Health, Saudi Arabia,

(9) Jalla Health Center, Ministry of Health, Saudi Arabia

Abstract

Background: Diabetes Mellitus (DM) is a pervasive global metabolic disorder characterized by chronic hyperglycemia, resulting from defects in insulin secretion, action, or both. With Type 2 Diabetes (T2DM) constituting 90% of cases and its prevalence rising sharply, DM represents a major public health burden and the seventh leading cause of mortality. The disease's complexity and its associated microvascular and macrovascular complications necessitate a comprehensive management strategy.

Aim: This article synthesizes the essential components for the effective, multidisciplinary management of diabetes, emphasizing a holistic approach that extends beyond glycemic control to prevent long-term complications and improve patient quality of life.

Methods: The approach integrates patient education, lifestyle modification (diet and exercise), and pharmacologic therapy. Treatment is tailored to the diabetes subtype: insulin is essential for Type 1 Diabetes (T1DM), while management of T2DM progresses from metformin and lifestyle changes to other oral agents, GLP-1 receptor agonists, SGLT2 inhibitors, and potentially insulin. A coordinated interprofessional team—including physicians, nurses, diabetes educators, nutritionists, pharmacists, and various specialists—is crucial for providing comprehensive care, from diagnosis to complication screening.

Results: Effective management achieves glycemic targets (e.g., HbA1c <7%) and significantly reduces the risk of devastating complications such as retinopathy, nephropathy, neuropathy, and cardiovascular disease. Landmark trials (LEADER, EMPA-REG OUTCOME) confirm that newer agents offer cardiovascular and renal protection. Individualized patient education is proven to enhance outcomes more effectively than generic interventions.

Conclusion: Optimal diabetes care requires a sustained, patient-centered, and collaborative model that addresses the full spectrum of the disease, from pathophysiology to prevention of complications.

Keywords: Diabetes Mellitus, Multidisciplinary Care, Glycemic Control, Patient Education, Complications, Interprofessional Team.

Introduction

Diabetes mellitus derives its name from a combination of Greek and Latin origins: the term "diabetes," meaning siphon or to pass through, and "mellitus," meaning sweet. Historical accounts indicate that the designation "diabetes" was first applied by Apollonius of Memphis between 250 and 300 BC. Ancient civilizations, including the Greeks, Indians, and Egyptians, recognized the distinctive

sweetness of urine in affected individuals, which contributed to the formal naming of the condition as Diabetes Mellitus. The pathophysiological understanding of diabetes progressed significantly in 1889, when Mering and Minkowski identified the critical role of the pancreas in the disease's development. This foundational discovery set the stage for the groundbreaking work of Banting, Best, and Collip in 1922, who successfully isolated and

purified insulin from bovine pancreatic tissue at the University of Toronto, providing the first effective therapeutic intervention for diabetes. Since that time, research and clinical advances have continuously enhanced the understanding and management of this pervasive metabolic disorder. Despite these advances, diabetes remains highly prevalent globally, representing a major public health concern and ranking as the seventh leading cause of mortality in the United States [1][2]. Diabetes mellitus is fundamentally a metabolic disorder characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The disease encompasses a spectrum of subtypes, including Type 1 diabetes mellitus (T1DM), Type 2 diabetes mellitus (T2DM), maturity-onset diabetes of the young (MODY), gestational diabetes, neonatal diabetes, and secondary forms linked to specific endocrinopathies or pharmacological agents such as corticosteroids. The primary forms, T1DM and T2DM, differ considerably in etiology and pathogenesis. T1DM arises predominantly from autoimmune-mediated destruction of pancreatic β -cells, leading to absolute insulin deficiency, and typically presents in children and adolescents. In contrast, T2DM primarily results from a combination of insulin resistance and relative insulin deficiency, with onset most commonly observed in middle-aged and older adults, often associated with prolonged hyperglycemia driven by suboptimal dietary patterns and sedentary lifestyles. These pathophysiological distinctions underpin variations in clinical presentation, therapeutic strategies, and long-term management approaches for each diabetes subtype, necessitating tailored interventions that address both metabolic control and associated complications [1][2].

Etiology

In the islets of Langerhans in the pancreas, there are two main subclasses of endocrine cells: insulin-producing beta cells and glucagon secreting alpha cells. Beta and alpha cells are continually changing their levels of hormone secretions based on the glucose environment. Without the balance between insulin and glucagon, the glucose levels become inappropriately skewed. In the case of DM, insulin is either absent and/or has impaired action (insulin resistance), and thus leads to hyperglycemia [1]. T1DM is characterized by the destruction of beta cells in the pancreas, typically secondary to an autoimmune process. The result is the absolute destruction of beta cells, and consequentially, insulin is absent or extremely low.

T2DM involves a more insidious onset where an imbalance between insulin levels and insulin sensitivity causes a functional deficit of insulin. Insulin resistance is multifactorial but commonly develops from obesity and aging. The genetic background for both types is critical as a risk factor. As the human genome gets further explored, there are different loci found that confer risk for DM.

Polymorphisms have been known to influence the risk for T1DM, including major histocompatibility complex (MHC) and human leukocyte antigen (HLA) [1]. T2DM involves a more complex interplay between genetics and lifestyle. There is clear evidence suggesting that T2DM has a stronger hereditary profile as compared to T1DM. The majority of patients with the disease have at least one parent with T2DM [2].




Fig. 1: Diabetes Mellitus Classification.

Monozygotic twins with one affected twin have a 90% likelihood of the other twin developing T2DM in his/her lifetime [3]. Approximately 50 polymorphisms to date have been described to contribute to the risk or protection for T2DM. These genes encode for proteins involved in various pathways leading to DM, including pancreatic development, insulin synthesis, secretion, and development, amyloid deposition in beta cells, insulin resistance, and impaired gluconeogenesis regulation. A genome-wide association study (GWAS) found genetic loci for transcription factor 7-like 2 gene (TCF7L2), which increases the risk for T2DM [4][5]. Other loci that have implications in the development of T2DM include NOTCH2, JAZF1, KCNQ1, and WFS1[6][7]. MODY is a heterogeneous disorder identified by non-insulin-dependent diabetes diagnosed at a young age (usually under 25 years). It carries an autosomal dominant transmission and does not involve autoantibodies as in T1DM. Several genes have implications in this disease, including mutations to hepatocyte nuclear factor-1-alpha (HNF1A) and the glucokinase (GCK) gene, which occurs in 52 to 65 and 15 to 32 percent of MODY cases, respectively [8][9]. The genetics of this disease are still unclear as some patients have mutations but never develop the disease, and others will develop clinical symptoms of MODY but have no identifiable mutation. Gestational diabetes is essentially diabetes that manifests during pregnancy. It is still unknown why it develops; however, some speculate that HLA antigens may play a role, specifically HLA DR2, 3, and 4. Excessive

proinsulin is also thought to play a role in gestational diabetes, and some suggest that proinsulin may induce beta-cell stress. Others believe that high concentrations of hormones such as progesterone, cortisol, prolactin, human placental lactogen, and estrogen may affect beta-cell function and peripheral insulin sensitivity [10]. Several endocrinopathies, including acromegaly, Cushing syndrome, glucagonoma, hyperthyroidism, hyperaldosteronism, and somatostatinomas, have been associated with glucose intolerance and diabetes mellitus, due to the inherent glucogenic action of the endogenous hormones excessively secreted in these conditions. Conditions like idiopathic hemochromatosis are associated with diabetes mellitus due to excessive iron deposition in the pancreas and the destruction of the beta cells.

Epidemiology

Diabetes mellitus represents a significant global health challenge, affecting approximately one in every eleven adults, with type 2 diabetes mellitus (T2DM) accounting for roughly 90% of these cases. Type 1 diabetes mellitus (T1DM), in contrast, presents predominantly in pediatric and adolescent populations, with incidence gradually increasing from birth and peaking between the ages of four to six years, followed by a second peak between ten and fourteen years [11]. Nearly 45% of pediatric cases manifest before the age of ten, and the overall prevalence in individuals under twenty years of age is estimated at 2.3 per 1,000 [12]. Unlike many autoimmune diseases that display a female predominance, childhood T1DM generally exhibits no substantial gender difference. However, certain populations, particularly older males of European descent above the age of thirteen, may demonstrate a higher susceptibility, with a male-to-female ratio of approximately 3:2 [13]. Epidemiological trends indicate a global increase in T1DM incidence, particularly in Europe, Australia, and the Middle East, where annual rates have been reported to rise between two and five percent [14][15][16]. In the United States, T1DM incidence has risen by about two percent annually across most age and ethnic groups, with elevated rates observed in Hispanic youth [17]. Despite these observations, the underlying etiological drivers of this rising trend remain incompletely understood. Data from structured healthcare repositories, such as the United States Military Health System, suggest a plateau in prevalence from 2007 to 2012, with prevalence approximating 1.5 per 1,000 and incidence ranging between 20.7 and 21.3 per 1,000 [18].

Type 2 diabetes mellitus traditionally manifests later in adulthood, although the global increase in adolescent obesity has contributed to earlier onset among younger populations. In the United States, T2DM affects approximately 9% of the total population, with prevalence increasing sharply to nearly 25% in individuals aged sixty-five years and

older. The International Diabetes Federation reported that in 2015, one in eleven adults aged twenty to seventy-nine years worldwide had diabetes, and projections suggest that this number will increase from 415 million to 642 million by 2040, with the most pronounced growth anticipated in populations undergoing socioeconomic transitions from low- to middle-income levels [19]. T2DM prevalence demonstrates notable variation across ethnic groups. In the United States, Black, Native American, Pima Indian, and Hispanic populations experience two- to six-fold higher prevalence compared to White populations [20][21]. These disparities underscore the combined influence of genetic susceptibility and environmental exposures. Comparative analyses of Pima Indians residing in distinct geographic and socioeconomic contexts illustrate this interaction; Pima Indians in Mexico exhibit a T2DM prevalence of 6.9%, whereas their counterparts in the United States present with a prevalence of 38% [22]. Such data highlight the interplay between hereditary predisposition, lifestyle factors, and environmental determinants in shaping the epidemiology of T2DM. Collectively, these epidemiological patterns demonstrate that diabetes mellitus, whether type 1 or type 2, represents a pervasive and escalating public health burden. The incidence and prevalence of both types of diabetes are influenced by a complex interplay of age, gender, ethnicity, genetics, and environmental factors. Rising global trends in obesity, urbanization, and aging populations, combined with socioeconomic transitions, are expected to further exacerbate the prevalence of T2DM, whereas the increasing recognition of autoimmune and genetic contributors continues to shape the understanding of T1DM distribution. Understanding these trends is crucial for effective public health planning, targeted interventions, and resource allocation to mitigate the morbidity and mortality associated with diabetes worldwide [22].

Pathophysiology

Diabetes mellitus is characterized by chronic hyperglycemia, arising from complex disruptions in insulin production, secretion, and action. The pathological mechanisms underlying the disease are multifactorial, involving a combination of genetic predisposition, metabolic derangements, and environmental factors. Hyperglycemia alone exerts deleterious effects on pancreatic beta-cell function, contributing to impaired insulin secretion and establishing a self-perpetuating cycle in which elevated glucose levels exacerbate metabolic dysfunction. Clinically, blood glucose concentrations exceeding 180 mg/dL are commonly considered hyperglycemic, although no universal threshold exists due to the heterogeneity of pathogenic mechanisms. Sustained hyperglycemia induces osmotic diuresis as renal glucose transporters become saturated, typically becoming symptomatic at serum glucose levels above

250 mg/dL, manifesting as polyuria and polydipsia. These osmotic effects represent a key early mechanism through which hyperglycemia produces systemic metabolic disturbances. Insulin resistance constitutes a central pathophysiological feature of type 2 diabetes mellitus (T2DM). It arises from a combination of excess circulating free fatty acids and proinflammatory cytokines, which disrupt insulin-mediated glucose transport and promote lipolysis. The resultant metabolic imbalance triggers compensatory hypersecretion of insulin; however, in many patients, pancreatic beta-cell capacity is insufficient to overcome resistance, leading to persistent hyperglycemia. Inappropriately elevated glucagon levels further exacerbate this dysregulation by stimulating hepatic gluconeogenesis, thereby contributing to the maintenance of high circulating glucose levels. In T2DM, the interplay between insulin resistance and relative insulin deficiency is critical, whereas in type 1 diabetes mellitus (T1DM), absolute insulin deficiency due to autoimmune beta-cell destruction predominates. Chronic hyperglycemia also promotes nonenzymatic glycation of proteins and lipids, a process measurable via glycated hemoglobin (HbA1c). Glycation leads to structural and functional alterations in small vessels, affecting organs such as the retina, kidneys, and peripheral nerves. The severity of glycation correlates directly with the magnitude and duration of hyperglycemia, accelerating the development of microvascular complications. Diabetic retinopathy, nephropathy, and neuropathy exemplify the consequences of prolonged hyperglycemia, with potential outcomes including vision loss, end-stage renal disease requiring dialysis, and peripheral neuropathy with risk of limb amputation [23]. These pathophysiological mechanisms underscore the critical importance of early glycemic control in preventing both acute and chronic complications, as well as in preserving long-term organ function and patient quality of life.

History and Physical

A comprehensive patient history is fundamental to the diagnosis of diabetes mellitus (DM), with particular emphasis on family history, autoimmune conditions, and risk factors for insulin resistance. Many patients remain asymptomatic during the early stages, and the disease is often identified incidentally through routine laboratory testing. When clinical manifestations are present, classical symptoms include polyuria, polydipsia, and unintentional weight loss, reflecting the metabolic dysregulation associated with hyperglycemia. Additional history should explore previous infections, delayed wound healing, or recurrent yeast infections, which may indicate chronic hyperglycemia and impaired immune function. Physical examination frequently reveals signs reflective of both acute and chronic complications of DM. Dehydration may manifest as poor skin turgor, while a distinctive fruity odor on the breath can indicate ketosis in patients with type 1

diabetes mellitus (T1DM) or during episodes of diabetic ketoacidosis (DKA). In acute metabolic derangements such as DKA, clinicians may observe Kussmaul respirations, fatigue, nausea, and vomiting, all indicative of compensatory respiratory and metabolic responses to acid-base imbalance. Funduscopic evaluation is essential to detect microvascular complications; findings may include macular hemorrhages, exudates, or dilated and occluded retinal venules. Proliferation of neovascular vessels in advanced diabetic retinopathy increases the risk of retinal hemorrhages and macular edema, potentially culminating in vision loss. Differentiation between T1DM and type 2 diabetes mellitus (T2DM) relies on clinical history and phenotypic features. T2DM often presents in overweight or obese individuals and may include physical signs of insulin resistance such as acanthosis nigricans, characterized by hyperpigmented, velvety skin patches in the neck, axillary, or inguinal regions. Chronic hyperglycemia in T2DM may lead to additional complications including blurred vision, peripheral neuropathy with numbness or pain, and delayed wound healing. Clinicians must routinely inquire about recent skin changes, particularly on the feet, as early identification of lesions can prevent progression to ulceration or infection. The diabetic foot examination, incorporating techniques such as the monofilament test to assess peripheral neuropathy, should be an integral component of every physical assessment. Collectively, thorough history-taking and meticulous physical examination are critical not only for diagnosis but also for risk stratification, early detection of complications, and guiding patient-specific management strategies [22][23].

Evaluation

The evaluation of diabetes mellitus (DM) involves a combination of clinical assessment and biochemical testing, aimed at accurately diagnosing the disease, stratifying risk, and guiding management. Type 1 diabetes mellitus (T1DM) is often diagnosed through a combination of characteristic clinical history and laboratory evidence of hyperglycemia. Standard diagnostic criteria include fasting plasma glucose levels exceeding 126 mg/dL, random glucose levels over 200 mg/dL, or hemoglobin A1c (HbA1c) levels above 6.5%, with or without the presence of autoantibodies such as glutamic acid decarboxylase (GAD) and insulin antibodies. The presence of these antibodies supports an autoimmune etiology, particularly relevant in pediatric or adolescent-onset cases where insulin deficiency is absolute [24][25]. Type 2 diabetes mellitus (T2DM) generally manifests more insidiously, often identified through routine laboratory testing before overt clinical symptoms emerge. Fasting glucose measurements and HbA1c are primary tools for early detection, with the oral glucose tolerance test (OGTT) serving as an adjunct for borderline or equivocal results. Prediabetes, frequently a precursor to T2DM, is defined by fasting blood

glucose between 100 and 125 mg/dL or a two-hour post-OGTT glucose concentration of 140 to 200 mg/dL, indicating impaired glucose regulation and elevated risk for progression [24][25]. The American Diabetes Association (ADA) delineates specific diagnostic thresholds for DM: HbA1c $\geq 6.5\%$, fasting plasma glucose ≥ 126 mg/dL after at least eight hours of no caloric intake, a two-hour plasma glucose ≥ 200 mg/dL during a 75-g OGTT, or a random plasma glucose ≥ 200 mg/dL in the presence of classic hyperglycemic symptoms, including polyuria, polydipsia, polyphagia, or unintentional weight loss. The ADA recommends routine screening for adults aged 45 years or older, independent of other risk factors. Complementarily, the United States Preventive Services Task Force suggests targeted screening for individuals aged 40 to 70 years who are overweight or obese, reflecting the strong association between adiposity and insulin resistance [26].

Blood Test Levels for Diagnosis of Diabetes and Prediabetes

	A1C (percent)	Fasting Plasma Glucose (mg/dL)	Oral Glucose Tolerance Test (mg/dL)
Diabetes	6.5 or above	126 or above	200 or above
Prediabetes	5.7 to 6.4	100 to 125	140 to 199
Normal	About 5	99 or below	139 or below

Definitions: mg = milligram, dL = deciliter
For all three tests, within the prediabetes range, the higher the test result, the greater the risk of diabetes.

Fig. 2: Diabetes Mellitus diagnosis.

Gestational diabetes mellitus (GDM) requires tailored evaluation. Universal screening is typically conducted between 24 and 28 weeks of gestation, beginning with a one-hour glucose challenge test. Blood glucose levels exceeding 140 mg/dL necessitate a confirmatory three-hour OGTT, with diagnostic thresholds defined as fasting ≥ 95 mg/dL, one-hour ≥ 180 mg/dL, two-hour ≥ 155 mg/dL, and three-hour ≥ 140 mg/dL. At least one abnormal value confirms the diagnosis [27]. Long-term management and monitoring of DM rely on laboratory assessment to prevent and detect complications. Home glucose monitoring allows for real-time trend analysis of hyperglycemia and hypoglycemia, while HbA1c testing provides a retrospective measure of glycemic control over approximately three months, reflecting erythrocyte lifespan. Screening for early diabetic nephropathy includes urine albumin testing, and assessment of cardiovascular risk factors necessitates serum lipid profiling. Given the elevated risk of thyroid dysfunction among patients with diabetes, annual thyroid-stimulating hormone (TSH) measurement is recommended to detect subclinical or overt hypothyroidism [24][25]. These comprehensive evaluation strategies are crucial for the timely diagnosis, risk stratification, and ongoing management

of patients with DM, facilitating optimized clinical outcomes and prevention of long-term complications.

Treatment / Management

The management of diabetes mellitus (DM) requires a comprehensive and multifaceted approach that encompasses patient education, lifestyle modifications, pharmacologic interventions, and regular monitoring to prevent long-term complications. Central to effective management is patient engagement and self-care. Educating patients about the disease, its potential complications, and the importance of adherence to therapy is fundamental. Individuals who actively participate in managing their diet, maintain regular physical activity of at least 150 minutes per week, and monitor their blood glucose levels independently demonstrate superior clinical outcomes [28]. Optimal glycemic control involves maintaining fasting glucose levels between 90 and 130 mg/dL and HbA1c below 7%, balancing the need to prevent hyperglycemia without inducing hypoglycemic events, which carry substantial morbidity and mortality risks. The cornerstone of treatment differs between diabetes subtypes. Type 1 diabetes mellitus (T1DM) arises from absolute insulin deficiency due to autoimmune destruction of pancreatic beta cells, necessitating exogenous insulin therapy as the primary treatment modality. Insulin can be delivered through multiple daily injections or continuous subcutaneous insulin infusion via an insulin pump. In contrast, type 2 diabetes mellitus (T2DM) initially benefits from lifestyle interventions, including dietary management and structured exercise programs. When these measures are insufficient, pharmacologic therapy is introduced, targeting insulin resistance or enhancing endogenous insulin secretion. Available drug classes include biguanides such as metformin, sulfonylureas, meglitinides, alpha-glucosidase inhibitors, thiazolidinediones, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, amylinomimetics, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors. Metformin remains the first-line pharmacologic therapy due to its efficacy in reducing both basal and postprandial glucose concentrations. In advanced T2DM, insulin therapy may become necessary when endogenous production fails to compensate for insulin resistance. For select patients with morbid obesity and comorbid conditions unresponsive to conventional therapy, bariatric surgery may serve as a therapeutic option to achieve long-term glycemic control [29]. GLP-1 receptor agonists, including liraglutide and semaglutide, provide additional cardiovascular benefits, while SGLT-2 inhibitors, such as empagliflozin and canagliflozin, confer renoprotective effects and reduce the risk of heart failure, highlighting the evolving role of antidiabetic agents beyond glycemic control [31][32].

Preventing microvascular complications necessitates consistent monitoring. Retinal

examinations are essential for early detection of diabetic retinopathy, performed by qualified healthcare professionals. Peripheral neuropathy should be assessed through neurological evaluation and monofilament testing, identifying patients at risk for ulceration and subsequent amputation. Patients should be instructed to perform daily foot inspections to detect lesions that may go unnoticed due to sensory deficits. Pharmacologic management of neuropathic pain includes low-dose tricyclic antidepressants, duloxetine, anticonvulsants, topical capsaicin, and other analgesic agents. Renal monitoring is achieved via urine microalbumin testing and estimated glomerular filtration rate (eGFR) assessment. Both ACE inhibitors and angiotensin receptor blockers (ARBs) are recommended for their antiproteinuric effects, delaying progression from microalbuminuria to overt nephropathy in patients with T1DM and T2DM. The FDA has specifically approved pregabalin and duloxetine for diabetic peripheral neuropathy, while tricyclic antidepressants and anticonvulsants continue to be utilized with varying degrees of efficacy. Cardiovascular risk management is a critical component of diabetes care. The ADA recommends routine blood pressure screening, aiming for a target of 130 mmHg systolic and 85 mmHg diastolic in diabetic patients [30]. Antihypertensive therapy may involve ACE inhibitors, ARBs, beta-blockers, calcium channel blockers, and diuretics, tailored to patient comorbidities and tolerability. Lipid management targets low-density lipoprotein cholesterol (LDL-C) below 100 mg/dL in patients without established cardiovascular disease and below 70 mg/dL in those with atherosclerotic cardiovascular disease (ASCVD). Statins are the first-line therapy for dyslipidemia in this population. Although low-dose aspirin may be considered for patients at high cardiovascular risk, its role in preventing cardiovascular events in diabetics remains controversial [31][32][33]. Overall, diabetes management is a dynamic, individualized process that requires integration of patient education, lifestyle modification, pharmacologic therapy, and vigilant monitoring for complications. Effective treatment extends beyond glycemic control to encompass cardiovascular protection, renal preservation, and mitigation of neuropathic and ophthalmic complications. Lifelong adherence and ongoing evaluation are essential for reducing morbidity and mortality and for optimizing long-term health outcomes in patients living with diabetes mellitus.

Differential Diagnosis

Diabetes mellitus (DM) encompasses a heterogeneous group of disorders characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. While type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), and maturity-onset diabetes of the young (MODY) represent the most commonly encountered forms, a comprehensive evaluation must consider other

conditions that can impair pancreatic function or disrupt glucose homeostasis.




Fig. 3: Emerging Treatment of Diabetes Mellitus.

Any disorder that damages pancreatic tissue has the potential to precipitate diabetes through either direct loss of beta-cell function or secondary mechanisms affecting insulin regulation [34]. Diseases of the exocrine pancreas are particularly relevant in the differential diagnosis of DM. Chronic pancreatitis, whether due to alcohol use, autoimmune mechanisms, or genetic predisposition, leads to progressive destruction of pancreatic parenchyma, often resulting in insulin deficiency and consequent hyperglycemia. Pancreatic malignancies, including adenocarcinoma of the pancreas, can similarly impair endocrine function, either through direct infiltration or secondary inflammation. Cystic fibrosis is another condition that affects exocrine pancreatic tissue, frequently causing fibrosis and obstruction of pancreatic ducts, which can compromise both exocrine and endocrine activity. Hereditary hemochromatosis, characterized by systemic iron overload, can result in iron deposition within pancreatic beta cells, leading to impaired insulin secretion and diabetes development [34].

Endocrine disorders and hormonal syndromes that influence glucose metabolism must also be considered. Excessive production of counter-regulatory hormones, such as catecholamines in pheochromocytoma, growth hormone in acromegaly, or cortisol in Cushing syndrome, can induce insulin resistance and secondary hyperglycemia. These conditions create a milieu in which normal pancreatic function is insufficient to maintain euglycemia, mimicking or exacerbating the presentation of classical diabetes. In addition, drug-induced insulin resistance remains a critical consideration. Chronic administration of glucocorticoids, estrogens, or certain antiepileptic medications such as phenytoin can impair insulin sensitivity or secretion, leading to hyperglycemia that may be misdiagnosed as primary diabetes. Gestational diabetes represents a unique subset in the differential, characterized by glucose intolerance first recognized during pregnancy [10]. It underscores the importance of temporally specific

endocrine changes and highlights the potential for transient or permanent alterations in glucose regulation. Thyroid disorders, including both hyperthyroidism and hypothyroidism, also warrant evaluation, as thyroid hormones profoundly affect carbohydrate metabolism and insulin sensitivity, potentially confounding the clinical presentation of DM. A thorough differential diagnosis is essential to guide appropriate laboratory evaluation, imaging, and genetic testing when indicated. Understanding the breadth of conditions that can lead to hyperglycemia ensures that clinicians do not overlook secondary forms of diabetes, which may require distinct therapeutic approaches compared to classical T1DM or T2DM. Recognition of these alternative etiologies is crucial for individualized patient care, as treatment strategies must account for underlying pathophysiology, comorbidities, and potential reversibility of the hyperglycemic state. Comprehensive evaluation enhances clinical decision-making and optimizes patient outcomes by facilitating timely and targeted interventions [10].

Pertinent Studies and Ongoing Trials

Recent research has increasingly focused on evaluating the cardiovascular outcomes associated with antidiabetic therapies, particularly in patients with type 2 diabetes mellitus (T2DM), who are at elevated risk for cardiovascular events. One of the landmark studies in this context is the LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results), a randomized, double-blinded clinical trial that enrolled approximately 10,000 patients with T2DM. Participants were assigned to receive either liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, or a placebo, and were followed over a period of roughly four years. The study demonstrated that liraglutide significantly reduced both cardiovascular mortality and all-cause mortality compared to placebo. Additionally, it lowered the incidence of nonfatal myocardial infarction and nonfatal stroke, suggesting a protective effect on major cardiovascular events in this high-risk population [1]. The LEADER trial has since established GLP-1 receptor agonists as a valuable component of comprehensive diabetes management, particularly for patients with preexisting cardiovascular disease. Parallel to GLP-1 research, the EMPA-REG OUTCOME trial investigated the cardiovascular effects of empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, in patients with T2DM at high cardiovascular risk. The trial revealed substantial reductions in all-cause mortality, cardiovascular mortality, and hospitalization for heart failure. Empagliflozin's benefits were attributed to its ability to promote osmotic diuresis and natriuresis, reduce cardiac preload, and improve ventricular function, alongside modest effects on blood pressure and glycemic control. These findings highlighted the role of SGLT2 inhibitors not only as glucose-lowering

agents but also as modulators of cardiovascular outcomes in diabetic patients [2].

Subsequently, the CANVAS trial (Canagliflozin Cardiovascular Assessment Study) examined the cardiovascular safety and efficacy of canagliflozin, another SGLT2 inhibitor. The study reported reductions in three-point major adverse cardiovascular events (MACE)—comprising cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke—as well as a decreased risk of hospitalization for heart failure. Mechanistic explanations for these effects include improved cardiac loading conditions due to enhanced natriuresis and osmotic diuresis, alongside potential renoprotective effects through reduced intraglomerular pressure and preservation of renal function. This trial reinforced the dual benefits of SGLT2 inhibitors, improving both cardiovascular and renal outcomes in T2DM [3]. Based on the compelling data from these mechanistic studies and large-scale clinical trials, ongoing research is now exploring the potential application of SGLT2 inhibitors beyond patients with diabetes. Large-scale trials are investigating the efficacy of these agents in individuals with heart failure, both with and without T2DM, aiming to determine whether the observed cardiovascular and renal benefits extend to non-diabetic populations. These investigations may redefine the therapeutic scope of SGLT2 inhibitors, positioning them as a key intervention in the management of cardiovascular and renal disease independently of glycemic status. Collectively, the LEADER, EMPA-REG OUTCOME, and CANVAS trials exemplify the paradigm shift in diabetes management toward a more holistic approach that addresses not only glycemic control but also cardiovascular and renal protection. These studies have influenced clinical guidelines, emphasizing the selection of antidiabetic agents with proven cardiovascular benefits in high-risk populations. The ongoing trials further aim to expand the evidence base, refine risk stratification, and optimize individualized therapeutic strategies, potentially transforming the standard of care for patients with T2DM and associated cardiovascular comorbidities [2].

Toxicity and Adverse Effect Management

The management of diabetes mellitus necessitates careful consideration of drug-related toxicities and adverse effects, as these can significantly impact patient outcomes and treatment adherence. Insulin therapy, which remains the cornerstone for Type 1 diabetes mellitus and advanced Type 2 diabetes mellitus, carries hypoglycemia as its most frequent and clinically significant adverse effect. Hypoglycemia can range from mild symptomatic episodes, characterized by tremors, sweating, and palpitations, to severe events involving loss of consciousness, seizures, or even death. Therefore, clinicians must educate patients on blood glucose

monitoring, recognition of hypoglycemic symptoms, and appropriate interventions, including dietary adjustments and glucagon administration when necessary [35]. Among oral antidiabetic agents, gastrointestinal disturbances are the most commonly reported adverse effects. Metformin, the first-line pharmacologic therapy for Type 2 diabetes mellitus, frequently induces nausea, diarrhea, and abdominal discomfort. More critically, metformin carries a rare but potentially fatal risk of lactic acidosis, particularly in patients with significant renal impairment. Clinical guidelines recommend discontinuation when the estimated glomerular filtration rate (eGFR) falls below 30 mL/min to mitigate this risk. Regular monitoring of renal function is therefore essential to ensure patient safety [35]. Sulfonylureas, while effective in enhancing insulin secretion, are associated with an increased risk of hypoglycemia, particularly in elderly patients or those with irregular meal patterns. There is also evidence suggesting that sulfonylurea therapy may be linked to elevated cardiovascular risk, emphasizing the need for judicious patient selection and ongoing monitoring [35]. Thiazolidinediones, once widely used for improving insulin sensitivity, have largely declined in clinical favor due to their adverse effect profile. These agents are known to cause fluid retention, exacerbate heart failure, and increase the risk of bone fractures, limiting their utility in populations at risk for these complications [36][37].

Newer pharmacologic classes, such as dipeptidyl peptidase-4 (DPP-4) inhibitors, generally demonstrate better gastrointestinal tolerability than metformin but may increase susceptibility to upper respiratory tract infections [38][39]. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, while offering cardioprotective and renoprotective benefits, can increase the incidence of urinary tract and genital infections due to elevated urinary glucose excretion [40]. Glucagon-like peptide-1 (GLP-1) receptor agonists share similar benefits with SGLT-2 inhibitors in reducing atherosclerotic cardiovascular disease events and are recommended as second-line agents following metformin, particularly in patients with established cardiovascular risk. Overall, effective management of diabetes requires not only glycemic control but also careful mitigation of drug-related toxicities. Clinicians must balance efficacy, patient comorbidities, and adverse effect profiles to optimize outcomes while minimizing harm. Regular monitoring, patient education, and individualized therapy remain essential strategies to safely manage the complexities associated with antidiabetic pharmacotherapy [39].

Prognosis

Diabetes mellitus continues to represent a major public health concern, ranking as the seventh leading cause of mortality in the United States as of 2015 [41]. The long-term outcomes of patients with diabetes are closely linked to the degree of glycemic control achieved throughout the disease course.

Persistent hyperglycemia is a critical determinant of both microvascular and macrovascular complications, and it substantially affects morbidity and mortality in affected individuals. Evidence from landmark studies underscores the importance of tight glucose regulation in modifying disease progression and improving clinical outcomes. The Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS) provided pivotal data demonstrating that chronic hyperglycemia in individuals with Type 1 and Type 2 diabetes, respectively, significantly increases the risk of microvascular complications, including retinopathy, nephropathy, and neuropathy [42][43]. These complications not only impair quality of life but also contribute to significant healthcare burdens. The studies highlight that even modest improvements in glycemic control can meaningfully reduce the incidence and severity of these complications. Furthermore, the trajectory of diabetes from prediabetes to overt disease is a critical window in which interventions may alter long-term outcomes. Patients who achieve normoglycemia during this transition demonstrate a markedly better prognosis, as early intervention can slow disease progression and reduce the risk of chronic complications [44]. Lifestyle modifications, including structured dietary management, regular physical activity, and weight control, are particularly effective during this period. These interventions, combined with pharmacologic therapy when indicated, can stabilize glucose homeostasis, delay the onset of complications, and improve overall survival [42][43]. In conclusion, prognosis in diabetes mellitus is heavily influenced by the degree of glycemic control, the timeliness of interventions, and patient adherence to both lifestyle and pharmacologic therapies. Early detection, vigilant monitoring, and sustained management of hyperglycemia are essential strategies to optimize long-term outcomes and reduce diabetes-related morbidity and mortality [42][43].

Complications

Diabetes mellitus (DM), irrespective of its subtype, is associated with a broad spectrum of complications that affect multiple organ systems, encompassing microvascular, macrovascular, and neuropathic sequelae. These complications are intricately linked to both the severity and the duration of hyperglycemia, emphasizing the critical importance of early and sustained glycemic control. Microvascular complications primarily involve small vessels and include retinopathy, nephropathy, and neuropathy, whereas macrovascular complications contribute to accelerated atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction and stroke. The coexistence of other comorbidities, such as dyslipidemia and hypertension, amplifies the risk for macrovascular events, further elevating morbidity and mortality among patients with DM [45]. Cardiovascular

complications remain particularly devastating, accounting for approximately two-thirds of deaths in diabetic populations. In individuals with type 2 diabetes mellitus (T2DM), fasting glucose levels exceeding 100 mg/dL are associated with a significantly heightened risk of ASCVD, and this risk may manifest even before overt hyperglycemia is apparent [46][47][48]. Diabetic retinopathy represents a major microvascular complication and is a leading cause of adult blindness among individuals aged 20 to 74 years in the United States. Annually, between 12,000 and 24,000 new cases of blindness are attributable to this condition. The pathophysiology of diabetic retinopathy involves chronic hyperglycemia-induced vascular damage within the retina, leading to microaneurysms, hemorrhages, exudates, and, in advanced cases, neovascularization. Management strategies encompass meticulous glycemic control alongside interventions such as laser photocoagulation, intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy, and pan-retinal photocoagulation for proliferative disease [49].

Renal involvement in DM constitutes another significant source of morbidity and mortality. Diabetes is the leading contributor to end-stage renal disease (ESRD) in the United States, with affected patients often requiring renal replacement therapy, including dialysis or kidney transplantation [49]. Microalbuminuria, defined as albumin excretion between 30 and 300 mg/day, serves as an early predictive marker for diabetic nephropathy and often precedes overt renal impairment. Progression to macroalbuminuria, characterized by albumin excretion exceeding 300 mg/day, accelerates the onset of ESRD. Routine monitoring using the albumin-to-creatinine ratio in random urine specimens provides a reliable and practical method for early detection. Persistent elevations on at least two of three measurements over six months confirm the diagnosis and warrant intervention to slow progression. Peripheral neuropathy, commonly associated with DM, contributes significantly to the risk of limb amputation. Neuropathy, combined with vasculopathy, increases susceptibility to foot ulcers, infections, and non-healing wounds. Regular foot examinations, including monofilament testing and patient education on daily self-inspections, are critical to mitigating the risk of severe infection and subsequent amputation [49]. The duration of diabetes is a principal risk factor for diabetic retinopathy. In type 1 diabetes mellitus (T1DM), retinopathy generally emerges approximately five years post-diagnosis, prompting recommendations for annual retinal examinations beginning at that time. Conversely, many patients with T2DM may already exhibit retinal changes at diagnosis. Epidemiological data indicate that 10% of patients develop nonproliferative retinopathy by ten years, 40% by

fifteen years, and 60% by twenty years, highlighting the progressive nature of vascular injury in the diabetic retina. Glycemic and blood pressure control significantly influence the onset and progression of retinopathy, while therapies such as anti-VEGF injections and laser photocoagulation mitigate the risk of visual loss. Sudden vision loss may result from vitreous hemorrhage, retinal vascular occlusion, retinal detachment, ischemic optic neuropathy, or advanced glaucoma, underscoring the need for vigilant ophthalmologic monitoring. Emerging evidence suggests that T2DM may also increase the risk of oncogenesis. Pioglitazone use has been associated with bladder cancer, whereas metformin appears to confer improved cancer-specific survival in prostate, pancreatic, breast, and colorectal malignancies. The precise mechanisms through which metformin exerts its potential anti-neoplastic effects remain under investigation [50][51].




Fig. 4: Complication of Diabetes mellitus.

Gestational diabetes mellitus (GDM) confers distinct obstetric and neonatal risks. Affected mothers face elevated rates of cesarean delivery and chronic hypertension. Neonates born to diabetic mothers are predisposed to macrosomia and hypoglycemia. Comparatively, women with T2DM tend to experience fewer pregnancy complications than those with T1DM [52]. Acute metabolic derangements remain the most life-threatening diabetic complications. Diabetic ketoacidosis (DKA), predominantly observed in T1DM, arises from insulin deficiency, commonly precipitated by missed doses, inadequate insulin administration, or concurrent infection. Insufficient insulin availability impairs cellular glucose uptake, necessitating lipid catabolism for energy and resulting in excessive ketone production. The consequent metabolic acidosis manifests as high anion-gap acidosis, osmotic diuresis, dehydration, electrolyte imbalances, and systemic symptoms including nausea, vomiting, and Kussmaul respirations. Hyperosmolar hyperglycemic state (HHS) represents a similar acute complication more frequently associated with T2DM, characterized by profound hyperglycemia, dehydration, polyuria, polydipsia, and altered mental status, typically in the absence of significant ketosis due to residual insulin production. Prompt recognition

and management of DKA and HHS necessitate insulin therapy, aggressive intravenous fluid replacement, and meticulous electrolyte correction, particularly of potassium, to prevent fatal sequelae [53][54].

Collectively, these complications underscore the multifaceted impact of diabetes on virtually every organ system. Chronic hyperglycemia induces both structural and functional alterations in vascular, renal, neurologic, and retinal tissues, whereas acute metabolic derangements pose immediate life-threatening risks. Long-term morbidity, including blindness, renal failure, cardiovascular disease, neuropathy, and amputations, substantially reduces quality of life and increases healthcare burdens. Management strategies integrating stringent glycemic control, regular screening for microvascular and macrovascular complications, vigilant monitoring for acute metabolic crises, and patient education remain the cornerstone for mitigating the extensive burden of diabetic complications. Advances in pharmacologic therapies, including GLP-1 receptor agonists and SGLT-2 inhibitors, have demonstrated additional protective effects against cardiovascular and renal complications, highlighting the evolving landscape of comprehensive diabetes care. Optimal outcomes depend on individualized treatment plans, interdisciplinary management, and proactive monitoring to prevent the cascade of progressive organ damage inherent to this complex chronic disease [54].

Patient Education

Patient education represents a cornerstone in the management of diabetes mellitus (DM), directly influencing both short- and long-term outcomes. Effective patient education extends beyond simple disease knowledge, encompassing the understanding and integration of lifelong lifestyle modifications, medication adherence, self-monitoring of blood glucose, and recognition of early complications. It is imperative for healthcare professionals to correct misconceptions that temporary or intermittent lifestyle changes are sufficient for glycemic control. Sustained modifications in diet, physical activity, and self-care behaviors remain essential throughout the patient's life. Failure to appreciate the chronic nature of diabetes and the necessity for ongoing self-management often leads to suboptimal glycemic control, increased complication rates, and greater morbidity. Empirical evidence supports the efficacy of individualized patient education over group-based interventions, particularly in patients with poorly controlled DM. Randomized controlled trials have demonstrated that patients receiving tailored, one-on-one education exhibited superior improvements in glycemic indices, self-management behaviors, and adherence to lifestyle interventions compared to those receiving generalized group instruction [55]. Individualized education allows healthcare professionals to address patient-specific barriers, cognitive limitations, psychosocial factors, and comorbidities that may impede optimal disease

management. Non-physician healthcare providers, including diabetes nurse educators, pharmacists, and dietitians, often have specialized training in patient education and may devote more time to these interventions than physicians in standard clinical practice. These professionals can deliver structured counseling on dietary carbohydrate control, caloric management, the timing and use of pharmacologic therapy, and self-monitoring techniques, all of which are associated with improved glycemic outcomes [54][55].

Additionally, patient education encompasses teaching patients to recognize early signs of acute metabolic decompensation, such as diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS), and to implement appropriate interventions or seek urgent medical care. Education on chronic complication prevention, including foot care, ocular health, and nephropathy screening, is equally critical. By fostering patient empowerment and promoting shared decision-making, education improves not only clinical outcomes but also psychosocial well-being and quality of life. The integration of technology further enhances patient education. Telemedicine, mobile health applications, and continuous glucose monitoring platforms provide real-time feedback to patients and enable remote engagement by healthcare providers. These technologies reinforce educational messages, support medication adherence, and allow for prompt intervention in cases of glycemic excursions. Ultimately, comprehensive, individualized education serves as a foundational pillar in diabetes care, reducing the burden of complications, improving patient self-efficacy, and enhancing overall disease management outcomes [55].

Other Issues

Emerging evidence suggests that amino acid metabolism plays a critical role in the pathogenesis of type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS). Metabolomic analyses have identified a significant elevation in branched-chain and aromatic amino acids, including isoleucine, phenylalanine, and tyrosine, which may precede the clinical onset of hyperglycemia by up to twelve years [56]. These alterations in amino acid profiles reflect early perturbations in metabolic homeostasis, contributing to insulin resistance, low-grade inflammation, and impaired glucose utilization. Recent studies further delineate the contribution of other metabolites, such as choline, L-carnitine, and trimethylamine-N-oxide (TMAO), to the pro-inflammatory milieu associated with nascent MetS, a cluster of cardiometabolic risk factors predisposing individuals to T2DM and cardiovascular disease [57]. In addition to these biomarkers, lysine deficiency has been correlated with heightened inflammatory responses and dysregulated glucose metabolism, suggesting potential therapeutic implications for dietary interventions. Supplementation with lysine

may attenuate systemic inflammation and improve glycemic control in at-risk individuals [58]. Further metabolomic investigations have identified increased levels of phosphatidylcholine 34:2 (PC 34:2), gamma-aminobutyric acid (GABA), and d-pyroglutamic acid (PGA) in early MetS, which correlate positively with markers of inflammation, highlighting their potential as early biomarkers for disease onset and progression [59][60]. Collectively, these findings underscore the complex interplay between amino acid metabolism, inflammatory signaling, and early metabolic dysfunction in the pathogenesis of T2DM, offering insights into novel diagnostic and therapeutic approaches. The role of these metabolites extends to disease screening, risk stratification, and potential therapeutic targets. By identifying early metabolic derangements, clinicians may implement preventive strategies in high-risk populations, potentially delaying or averting the progression to overt diabetes. Moreover, these discoveries provide opportunities to explore personalized nutritional interventions, metabolic modulators, and pharmacologic strategies that target specific pathways implicated in metabolic and inflammatory dysregulation. As research in metabolomics and systems biology advances, it may redefine current approaches to risk assessment and early intervention, ultimately improving long-term outcomes for patients at risk of T2DM and related cardiometabolic disorders [56].

Enhancing Healthcare Team Outcomes

Effective diabetes management necessitates a coordinated, interprofessional team approach, given the multifactorial nature of the disease and the breadth of complications that may arise. Primary care clinicians play a pivotal role in early identification and longitudinal monitoring of DM; however, optimal patient care requires the integration of multiple specialists and allied health professionals. Nurse practitioners and physician assistants contribute significantly to patient follow-up, monitoring therapeutic efficacy, and ensuring adherence to care plans. Nutritionists and certified diabetes educators provide targeted guidance on dietary modifications, exercise regimens, and at-home glucose monitoring strategies, thereby reinforcing patient self-management and lifestyle adherence. Specialists including ophthalmologists, neurologists, podiatrists, and nephrologists play a critical role in the prevention and early detection of microvascular complications, enabling timely interventions to reduce the risk of vision loss, neuropathy-related injuries, and renal impairment. Endocrinologists are often consulted for complex or refractory cases, providing expertise in advanced pharmacologic regimens and insulin titration. Pharmacists are integral to comprehensive care, ensuring correct medication dosing, minimizing polypharmacy, monitoring potential drug interactions, and educating patients on proper medication administration and disease understanding.

Empirical evidence underscores the impact of individualized patient education delivered within an interprofessional framework. Sperl-Hillen et al. demonstrated that patients with suboptimally controlled diabetes achieved superior glycemic control, psychosocial outcomes, and behavioral adherence when engaged in individualized education compared to traditional group-based approaches [55]. This finding emphasizes the importance of collaborative communication among clinicians, educators, pharmacists, and specialists to develop patient-specific care plans. The integration of diverse healthcare professionals ensures that all aspects of diabetes management, including pharmacologic therapy, lifestyle modification, complication screening, and psychosocial support, are addressed comprehensively, ultimately leading to improved clinical outcomes and enhanced patient quality of life. By fostering interprofessional collaboration, healthcare teams can optimize patient-centered care, ensuring that educational, therapeutic, and preventive interventions are harmonized across disciplines. Structured care pathways, regular communication, and shared decision-making between healthcare providers and patients are essential components of this model, enhancing adherence, glycemic control, and long-term complication prevention. In conclusion, the synergy between patient education, metabolic insights, and interprofessional collaboration forms the cornerstone of effective diabetes management, providing a framework for improved outcomes and sustainable chronic disease control.

Patient Education

Patient education represents a cornerstone in the management of diabetes mellitus (DM), directly influencing both short- and long-term outcomes. Effective patient education extends beyond simple disease knowledge, encompassing the understanding and integration of lifelong lifestyle modifications, medication adherence, self-monitoring of blood glucose, and recognition of early complications. It is imperative for healthcare professionals to correct misconceptions that temporary or intermittent lifestyle changes are sufficient for glycemic control. Sustained modifications in diet, physical activity, and self-care behaviors remain essential throughout the patient's life. Failure to appreciate the chronic nature of diabetes and the necessity for ongoing self-management often leads to suboptimal glycemic control, increased complication rates, and greater morbidity. Empirical evidence supports the efficacy of individualized patient education over group-based interventions, particularly in patients with poorly controlled DM. Randomized controlled trials have demonstrated that patients receiving tailored, one-on-one education exhibited superior improvements in glycemic indices, self-management behaviors, and adherence to lifestyle interventions compared to those receiving generalized group instruction [55].

Individualized education allows healthcare professionals to address patient-specific barriers, cognitive limitations, psychosocial factors, and comorbidities that may impede optimal disease management. Non-physician healthcare providers, including diabetes nurse educators, pharmacists, and dietitians, often have specialized training in patient education and may devote more time to these interventions than physicians in standard clinical practice. These professionals can deliver structured counseling on dietary carbohydrate control, caloric management, the timing and use of pharmacologic therapy, and self-monitoring techniques, all of which are associated with improved glycemic outcomes. Additionally, patient education encompasses teaching patients to recognize early signs of acute metabolic decompensation, such as diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS), and to implement appropriate interventions or seek urgent medical care. Education on chronic complication prevention, including foot care, ocular health, and nephropathy screening, is equally critical. By fostering patient empowerment and promoting shared decision-making, education improves not only clinical outcomes but also psychosocial well-being and quality of life. The integration of technology further enhances patient education. Telemedicine, mobile health applications, and continuous glucose monitoring platforms provide real-time feedback to patients and enable remote engagement by healthcare providers. These technologies reinforce educational messages, support medication adherence, and allow for prompt intervention in cases of glycemic excursions. Ultimately, comprehensive, individualized education serves as a foundational pillar in diabetes care, reducing the burden of complications, improving patient self-efficacy, and enhancing overall disease management outcomes.

Other Issues

Emerging evidence suggests that amino acid metabolism plays a critical role in the pathogenesis of type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS). Metabolomic analyses have identified a significant elevation in branched-chain and aromatic amino acids, including isoleucine, phenylalanine, and tyrosine, which may precede the clinical onset of hyperglycemia by up to twelve years [56]. These alterations in amino acid profiles reflect early perturbations in metabolic homeostasis, contributing to insulin resistance, low-grade inflammation, and impaired glucose utilization. Recent studies further delineate the contribution of other metabolites, such as choline, L-carnitine, and trimethylamine-N-oxide (TMAO), to the pro-inflammatory milieu associated with nascent MetS, a cluster of cardiometabolic risk factors predisposing individuals to T2DM and cardiovascular disease [57]. In addition to these biomarkers, lysine deficiency has been correlated with heightened inflammatory responses and dysregulated glucose metabolism,

suggesting potential therapeutic implications for dietary interventions. Supplementation with lysine may attenuate systemic inflammation and improve glycemic control in at-risk individuals [58]. Further metabolomic investigations have identified increased levels of phosphatidylcholine 34:2 (PC 34:2), gamma-aminobutyric acid (GABA), and d-pyroglyutamic acid (PGA) in early MetS, which correlate positively with markers of inflammation, highlighting their potential as early biomarkers for disease onset and progression [59][60]. Collectively, these findings underscore the complex interplay between amino acid metabolism, inflammatory signaling, and early metabolic dysfunction in the pathogenesis of T2DM, offering insights into novel diagnostic and therapeutic approaches. The role of these metabolites extends to disease screening, risk stratification, and potential therapeutic targets. By identifying early metabolic derangements, clinicians may implement preventive strategies in high-risk populations, potentially delaying or averting the progression to overt diabetes. Moreover, these discoveries provide opportunities to explore personalized nutritional interventions, metabolic modulators, and pharmacologic strategies that target specific pathways implicated in metabolic and inflammatory dysregulation. As research in metabolomics and systems biology advances, it may redefine current approaches to risk assessment and early intervention, ultimately improving long-term outcomes for patients at risk of T2DM and related cardiometabolic disorders [59][60].

Enhancing Healthcare Team Outcomes

Effective diabetes management necessitates a coordinated, interprofessional team approach, given the multifactorial nature of the disease and the breadth of complications that may arise. Primary care clinicians play a pivotal role in early identification and longitudinal monitoring of DM; however, optimal patient care requires the integration of multiple specialists and allied health professionals. Nurse practitioners and physician assistants contribute significantly to patient follow-up, monitoring therapeutic efficacy, and ensuring adherence to care plans. Nutritionists and certified diabetes educators provide targeted guidance on dietary modifications, exercise regimens, and at-home glucose monitoring strategies, thereby reinforcing patient self-management and lifestyle adherence. Specialists including ophthalmologists, neurologists, podiatrists, and nephrologists play a critical role in the prevention and early detection of microvascular complications, enabling timely interventions to reduce the risk of vision loss, neuropathy-related injuries, and renal impairment. Endocrinologists are often consulted for complex or refractory cases, providing expertise in advanced pharmacologic regimens and insulin titration. Pharmacists are integral to comprehensive care, ensuring correct medication dosing, minimizing polypharmacy, monitoring potential drug interactions, and educating patients on proper medication

administration and disease understanding. Empirical evidence underscores the impact of individualized patient education delivered within an interprofessional framework. Sperl-Hillen et al. demonstrated that patients with suboptimally controlled diabetes achieved superior glycemic control, psychosocial outcomes, and behavioral adherence when engaged in individualized education compared to traditional group-based approaches [55]. This finding emphasizes the importance of collaborative communication among clinicians, educators, pharmacists, and specialists to develop patient-specific care plans. The integration of diverse healthcare professionals ensures that all aspects of diabetes management, including pharmacologic therapy, lifestyle modification, complication screening, and psychosocial support, are addressed comprehensively, ultimately leading to improved clinical outcomes and enhanced patient quality of life. By fostering interprofessional collaboration, healthcare teams can optimize patient-centered care, ensuring that educational, therapeutic, and preventive interventions are harmonized across disciplines. Structured care pathways, regular communication, and shared decision-making between healthcare providers and patients are essential components of this model, enhancing adherence, glycemic control, and long-term complication prevention. In conclusion, the synergy between patient education, metabolic insights, and interprofessional collaboration forms the cornerstone of effective diabetes management, providing a framework for improved outcomes and sustainable chronic disease control.

Conclusion:

In conclusion, the effective management of Diabetes Mellitus demands a comprehensive, integrated, and lifelong strategy that transcends simple glycemic control. The profound morbidity and mortality associated with DM stem from its systemic microvascular and macrovascular complications, including retinopathy, nephropathy, neuropathy, and cardiovascular disease. Therefore, successful treatment requires a holistic approach that rigorously combines patient education, sustained lifestyle modifications, and a tailored pharmacologic regimen. The paradigm of care has evolved significantly, with landmark clinical trials underscoring the importance of selecting medications not only for their glucose-lowering efficacy but also for their proven cardiovascular and renal benefits, as demonstrated by GLP-1 receptor agonists and SGLT2 inhibitors. Crucially, no single practitioner can manage this complex chronic disease alone. Optimal outcomes are achieved through a coordinated, interprofessional team model. This team integrates the expertise of primary care physicians, endocrinologists, nurses, diabetes educators, nutritionists, pharmacists, and specialists in ophthalmology, podiatry, and nephrology. Such collaboration ensures that every

aspect of the patient's health—from medication adherence and dietary management to regular complication screening and psychosocial support—is addressed comprehensively. By fostering this synergistic, patient-centered approach, healthcare systems can significantly improve quality of life, reduce the burden of complications, and alter the trajectory of this pervasive global health challenge.

References:

1. Rajaei E, Jalali MT, Shahrabi S, Asnafi AA, Pezeshki SMS. HLAs in Autoimmune Diseases: Dependable Diagnostic Biomarkers? *Current rheumatology reviews*. 2019;15(4):269-276. doi: 10.2174/1573397115666190115143226.
2. Klein BE, Klein R, Moss SE, Cruickshanks KJ. Parental history of diabetes in a population-based study. *Diabetes care*. 1996 Aug;19(8):827-30
3. Barnett AH, Eff C, Leslie RD, Pyke DA. Diabetes in identical twins. A study of 200 pairs. *Diabetologia*. 1981 Feb;20(2):87-93
4. Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, Saxena R, Voight BF, Lyssenko V, Burt NP, de Bakker PI, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, Hughes TE, Groop L, Altschuler D, Almgren P, Florez JC, Meyer J, Ardlie K, Bengtsson Boström K, Isomaa B, Lettre G, Lindblad U, Lyon HN, Melander O, Newton-Cheh C, Nilsson P, Orho-Melander M, Råstam L, Speliotes EK, Taskinen MR, Tuomi T, Guiducci C, Berglund A, Carlson J, Gianniny L, Hackett R, Hall L, Holmkvist J, Laurila E, Sjögren M, Sterner M, Surti A, Svensson M, Svensson M, Tewhey R, Blumenstiel B, Parkin M, Defelice M, Barry R, Brodeur W, Camarata J, Chia N, Fava M, Gibbons J, Handsaker B, Healy C, Nguyen K, Gates C, Sougnez C, Gage D, Nizzari M, Gabriel SB, Chirn GW, Ma Q, Parikh H, Richardson D, Ricke D, Purcell S. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. *Science (New York, N.Y.)*. 2007 Jun 1;316(5829):1331-6
5. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, Balkau B, Heude B, Charpentier G, Hudson TJ, Montpetit A, Pshzhetsky AV, Prentki M, Posner BI, Balding DJ, Meyre D, Polychronakos C, Froguel P. A genome-wide association study identifies novel risk loci for type 2 diabetes. *Nature*. 2007 Feb 22;445(7130):881-5
6. Yasuda K, Miyake K, Horikawa Y, Hara K, Osawa H, Furuta H, Hirota Y, Mori H,

- Jonsson A, Sato Y, Yamagata K, Hinokio Y, Wang HY, Tanahashi T, Nakamura N, Oka Y, Iwasaki N, Iwamoto Y, Yamada Y, Seino Y, Maegawa H, Kashiwagi A, Takeda J, Maeda E, Shin HD, Cho YM, Park KS, Lee HK, Ng MC, Ma RC, So WY, Chan JC, Lyssenko V, Tuomi T, Nilsson P, Groop L, Kamatani N, Sekine A, Nakamura Y, Yamamoto K, Yoshida T, Tokunaga K, Itakura M, Makino H, Nanjo K, Kadowaki T, Kasuga M. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. *Nature genetics*. 2008 Sep;40(9):1092-7. doi: 10.1038/ng.207.
7. Zeggini E, Scott LJ, Saxena R, Voight BF, Marchini JL, Hu T, de Bakker PI, Abecasis GR, Almgren P, Andersen G, Ardlie K, Boström KB, Bergman RN, Bonnycastle LL, Borch-Johnsen K, Burtt NP, Chen H, Chines PS, Daly MJ, Deodhar P, Ding CJ, Doney AS, Duren WL, Elliott KS, Erdos MR, Frayling TM, Freathy RM, Gianniny L, Grallert H, Grarup N, Groves CJ, Guiducci C, Hansen T, Herder C, Hitman GA, Hughes TE, Isomaa B, Jackson AU, Jørgensen T, Kong A, Kubalanza K, Kuruvilla FG, Kuusisto J, Langenberg C, Lango H, Lauritzen T, Li Y, Lindgren CM, Lyssenko V, Marville AF, Meisinger C, Midthjell K, Mohlke KL, Morken MA, Morris AD, Narisu N, Nilsson P, Owen KR, Palmer CN, Payne F, Perry JR, Pettersen E, Platou C, Prokopenko I, Qi L, Qin L, Rayner NW, Rees M, Roix JJ, Sandback A, Shields B, Sjögren M, Steinthorsdottir V, Stringham HM, Swift AJ, Thorleifsson G, Thorsteinsdottir U, Timpson NJ, Tuomi T, Tuomilehto J, Walker M, Watanabe RM, Weedon MN, Willer CJ, Wellcome Trust Case Control Consortium, Illig T, Hveem K, Hu FB, Laakso M, Stefansson K, Pedersen O, Wareham NJ, Barroso I, Hattersley AT, Collins FS, Groop L, McCarthy MI, Boehnke M, Altshuler D. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. *Nature genetics*. 2008 May;40(5):638-45. doi: 10.1038/ng.120.
 8. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. *The New England journal of medicine*. 2001 Sep 27;345(13):971-80
 9. Shields BM, Hicks S, Shepherd MH, Colclough K, Hattersley AT, Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? *Diabetologia*. 2010 Dec;53(12):2504-8. doi: 10.1007/s00125-010-1799-4.
 10. Kühl C. Etiology and pathogenesis of gestational diabetes. *Diabetes care*. 1998 Aug;21 Suppl 2():B19-26
 11. Felner EI, Klitz W, Ham M, Lazaro AM, Stastny P, Dupont B, White PC. Genetic interaction among three genomic regions creates distinct contributions to early- and late-onset type 1 diabetes mellitus. *Pediatric diabetes*. 2005 Dec;6(4):213-20
 12. Writing Group for the SEARCH for Diabetes in Youth Study Group, Dabelea D, Bell RA, D'Agostino RB Jr, Imperatore G, Johansen JM, Linder B, Liu LL, Loots B, Marcovina S, Mayer-Davis EJ, Pettitt DJ, Waitzfelder B. Incidence of diabetes in youth in the United States. *JAMA*. 2007 Jun 27;297(24):2716-24
 13. Gale EA, Gillespie KM. Diabetes and gender. *Diabetologia*. 2001 Jan;44(1):3-15
 14. Mamoulakis D, Galanakis E, Bicouvarakis S, Paraskakis E, Sbyrakakis S. Epidemiology of childhood type I diabetes in Crete, 1990-2001. *Acta paediatrica (Oslo, Norway : 1992)*. 2003 Jun;92(6):737-9
 15. Tuomilehto J. The emerging global epidemic of type 1 diabetes. *Current diabetes reports*. 2013 Dec;13(6):795-804. doi: 10.1007/s11892-013-0433-5.
 16. Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G, EURODIAB Study Group. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. *Lancet (London, England)*. 2009 Jun 13;373(9680):2027-33. doi: 10.1016/S0140-6736(09)60568-7.
 17. Vehik K, Hamman RF, Lezotte D, Norris JM, Klingensmith G, Bloch C, Rewers M, Dabelea D. Increasing incidence of type 1 diabetes in 0- to 17-year-old Colorado youth. *Diabetes care*. 2007 Mar;30(3):503-9
 18. Rush T, McGeary M, Sicignano N, Buryk MA. A plateau in new onset type 1 diabetes: Incidence of pediatric diabetes in the United States Military Health System. *Pediatric diabetes*. 2018 Aug;19(5):917-922. doi: 10.1111/pedi.12659.
 19. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. *Nature reviews. Endocrinology*. 2018 Feb;14(2):88-98. doi: 10.1038/nrendo.2017.151.
 20. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination

- Survey, 1988-1994. *Diabetes care*. 1998 Apr;21(4):518-24
21. Carter JS, Pugh JA, Monterrosa A. Non-insulin-dependent diabetes mellitus in minorities in the United States. *Annals of internal medicine*. 1996 Aug 1;125(3):221
 22. Schulz LO, Bennett PH, Ravussin E, Kidd JR, Kidd KK, Esparza J, Valencia ME. Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. *Diabetes care*. 2006 Aug;29(8):1866-71
 23. Unger RH, Orci L. Paracrinology of islets and the paracrinopathy of diabetes. *Proceedings of the National Academy of Sciences of the United States of America*. 2010 Sep 14;107(37):16009-12. doi: 10.1073/pnas.1006639107.
 24. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes care*. 2010 Jan;33 Suppl 1(Suppl 1):S62-9. doi: 10.2337/dc10-S062.
 25. American Diabetes Association. Standards of medical care in diabetes--2012. *Diabetes care*. 2012 Jan;35 Suppl 1(Suppl 1):S11-63. doi: 10.2337/dc12-s011.
 26. Selph S, Dana T, Bougatsos C, Blazina I, Patel H, Chou R. Screening for Abnormal Glucose and Type 2 Diabetes Mellitus: A Systematic Review to Update the 2008 U.S. Preventive Services Task Force Recommendation. 2015 Apr
 27. Karagiannis T, Bekiari E, Manolopoulos K, Paletas K, Tsapas A. Gestational diabetes mellitus: why screen and how to diagnose. *Hippokratia*. 2010 Jul;14(3):151-4
 28. Umpierre D, Ribeiro PA, Kramer CK, Leitão CB, Zucatti AT, Azevedo MJ, Gross JL, Ribeiro JP, Schaan BD. Physical activity advice only or structured exercise training and association with HbA1c levels in type 2 diabetes: a systematic review and meta-analysis. *JAMA*. 2011 May 4;305(17):1790-9. doi: 10.1001/jama.2011.576.
 29. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *The New England journal of medicine*. 2002 Feb 7;346(6):393-403
 30. de Boer IH, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P, Rossing P, Zoungas S, Bakris G. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. *Diabetes care*. 2000 Jan;23 Suppl 1():S61-2
 31. American Diabetes Association. Aspirin therapy in diabetes. *Diabetes care*. 2000 Jan;23 Suppl 1():S61-2
 32. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y, Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. *JAMA*. 2008 Nov 12;300(18):2134-41. doi: 10.1001/jama.2008.623.
 33. Saito Y, Morimoto T, Ogawa H, Nakayama M, Uemura S, Doi N, Jinnouchi H, Waki M, Soejima H, Sugiyama S, Okada S, Akai Y, Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial Investigators. Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. *Diabetes care*. 2011 Feb;34(2):280-5. doi: 10.2337/dc10-1615.
 34. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. *The New England journal of medicine*. 2008 Oct 9;359(15):1577-89. doi: 10.1056/NEJMoa0806470.
 35. Zeller M, Danchin N, Simon D, Vahanian A, Lorgis L, Cottin Y, Berland J, Gueret P, Wyart P, Deturck R, Tabone X, Machecourt J, Leclercq F, Drouet E, Mulak G, Bataille V, Cambou JP, Ferrieres J, Simon T, French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction investigators. Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction. *The Journal of clinical endocrinology and metabolism*. 2010 Nov;95(11):4993-5002. doi: 10.1210/jc.2010-0449.
 36. Chang CS, Tsai PJ, Sung JM, Chen JY, Ho LC, Pandya K, Maeda N, Tsai YS. Diuretics prevent thiazolidinedione-induced cardiac hypertrophy without compromising insulin-sensitizing effects in mice. *The American journal of pathology*. 2014 Feb;184(2):442-53. doi: 10.1016/j.ajpath.2013.10.020.
 37. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. *CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne*. 2009 Jan 6;180(1):32-9. doi: 10.1503/cmaj.080486.
 38. Willemens MJ, Mantel-Teeuwisse AK, Straus SM, Meyboom RH, Egberts TC, Leufkens

- HG. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analysis in the World Health Organization VigiBase. *Diabetes care*. 2011 Feb;34(2):369-74. doi: 10.2337/dc10-1771.
39. Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD, Goldstein BJ, Sitagliptin Study 049 Group. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. *Diabetes, obesity & metabolism*. 2010 Mar;12(3):252-61. doi: 10.1111/j.1463-1326.2009.01187.x.
 40. Unnikrishnan AG, Kalra S, Purandare V, Vasawala H. Genital Infections with Sodium Glucose Cotransporter-2 Inhibitors: Occurrence and Management in Patients with Type 2 Diabetes Mellitus. *Indian journal of endocrinology and metabolism*. 2018 Nov-Dec;22(6):837-842. doi: 10.4103/ijem.IJEM_159_17.
 41. Heron M. Deaths: Leading Causes for 2015. National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System. 2017 Nov;66(5):1-76
 42. Albers JW, Herman WH, Pop-Busui R, Feldman EL, Martin CL, Cleary PA, Waberski BH, Lachin JM, Diabetes Control and Complications Trial /Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. *Diabetes care*. 2010 May;33(5):1090-6. doi: 10.2337/dc09-1941.
 43. . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. *Lancet (London, England)*. 1998 Sep 12;352(9131):837-53
 44. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE, Diabetes Prevention Program Research Group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. *Lancet (London, England)*. 2012 Jun 16;379(9833):2243-51. doi: 10.1016/S0140-6736(12)60525-X.
 45. Yamazaki D, Hitomi H, Nishiyama A. Hypertension with diabetes mellitus complications. *Hypertension research : official journal of the Japanese Society of Hypertension*. 2018 Mar;41(3):147-156. doi: 10.1038/s41440-017-0008-y.
 46. Wannamethee SG, Shaper AG, Whincup PH, Lennon L, Sattar N. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. *Archives of internal medicine*. 2011 Mar 14;171(5):404-10. doi: 10.1001/archinternmed.2011.2.
 47. Rao Kondapally Seshasai S, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J, Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. *The New England journal of medicine*. 2011 Mar 3;364(9):829-841. doi: 10.1056/NEJMoa1008862.
 48. Stern MP. Do non-insulin-dependent diabetes mellitus and cardiovascular disease share common antecedents? *Annals of internal medicine*. 1996 Jan 1;124(1 Pt 2):110-6
 49. Forbes JM, Cooper ME. Mechanisms of diabetic complications. *Physiological reviews*. 2013 Jan;93(1):137-88. doi: 10.1152/physrev.00045.2011.
 50. Tseng CH. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. *Diabetologia*. 2011 Aug;54(8):2009-15. doi: 10.1007/s00125-011-2171-z.
 51. Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. *The oncologist*. 2013;18(12):1248-55. doi: 10.1634/theoncologist.2013-0111.
 52. Murphy HR, Steel SA, Roland JM, Morris D, Ball V, Campbell PJ, Temple RC, East Anglia Study Group for Improving Pregnancy Outcomes in Women with Diabetes (EASIPOD). Obstetric and perinatal outcomes in pregnancies complicated by Type 1 and Type 2 diabetes: influences of glycaemic control, obesity and social disadvantage. *Diabetic medicine : a journal of the British Diabetic Association*. 2011 Sep;28(9):1060-7. doi: 10.1111/j.1464-5491.2011.03333.x.
 53. Martínez E, Portillo N, Lizarralde E, Grau G, Vela A, Rodríguez A, Rica I. For Debate: Paediatric T1DM: DKA is Still a Problem. *Pediatric endocrinology reviews : PER*. 2018

- Dec:16(2):233-239. doi: 10.17458/per.vol16.2018.mpr.fd.t1dmdka.
54. Karslioglu French E, Donihi AC, Korytkowski MT. Diabetic ketoacidosis and hyperosmolar hyperglycemic syndrome: review of acute decompensated diabetes in adult patients. *BMJ (Clinical research ed.)*. 2019 May 29;365():l1114. doi: 10.1136/bmj.l1114.
55. Sperl-Hillen J, Beaton S, Fernandes O, Von Worley A, Vazquez-Benitez G, Parker E, Hanson A, Lavin-Tompkins J, Glasrud P, Davis H, Adams K, Parsons W, Spain CV. Comparative effectiveness of patient education methods for type 2 diabetes: a randomized controlled trial. *Archives of internal medicine*. 2011 Dec 12;171(22):2001-10. doi: 10.1001/archinternmed.2011.507.
56. Wang TJ, Larson MG, Vasani RS, Cheng S, Rhee EP, McCabe E, Lewis GD, Fox CS, Jacques PF, Fernandez C, O'Donnell CJ, Carr SA, Mootha VK, Florez JC, Souza A, Melander O, Clish CB, Gerszten RE. Metabolite profiles and the risk of developing diabetes. *Nature medicine*. 2011 Apr;17(4):448-53. doi: 10.1038/nm.2307.
57. Lent-Schochet D, Silva R, McLaughlin M, Huet B, Jialal I. Changes to trimethylamine-N-oxide and its precursors in nascent metabolic syndrome. *Hormone molecular biology and clinical investigation*. 2018 Apr 18;35(2):. pii: /j/hmbci.2018.35.issue-2/hmbci-2018-0015/hmbci-2018-0015.xml. doi: 10.1515/hmbci-2018-0015.
58. Reddy P, Leong J, Jialal I. Amino acid levels in nascent metabolic syndrome: A contributor to the pro-inflammatory burden. *Journal of diabetes and its complications*. 2018 May;32(5):465-469. doi: 10.1016/j.jdiacomp.2018.02.005.
59. Shim K, Gulhar R, Jialal I. Exploratory metabolomics of nascent metabolic syndrome. *Journal of diabetes and its complications*. 2019 Mar;33(3):212-216. doi: 10.1016/j.jdiacomp.2018.12.002
60. Ramakrishnan N, Denna T, Devaraj S, Adams-Huet B, Jialal I. Exploratory lipidomics in patients with nascent Metabolic Syndrome. *Journal of diabetes and its complications*. 2018 Aug;32(8):791-794. doi: 10.1016/j.jdiacomp.2018.05.014.